Physician profile
William Payne
NPI 1467563916
$1,327.92
in general payments reported to CMS, 2019-2025
15 companies · $219 in 2025
The $219 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $129 · 2021: $141 · 2022: $247 · 2023: $188 · 2024: $103 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $510.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $295.23 | 2019-2025 | |
| Glaxosmithkline, LLC. | $208.13 | 2019-2025 | Bexsero, Pediarix |
| Ironshore Pharmaceuticals INC. | $200.51 | 2019-2023 | Jornay Pm |
| Pfizer INC. | $166.13 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $142.54 | 2020-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Corium, LLC | $109.82 | 2022-2023 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $69.91 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $24.68 | 2019 | |
| Supernus Pharmaceuticals, INC. | $21.14 | 2023 | Qelbree |
| Collegium Pharmaceutical, INC. | $19.85 | 2025 | Jornay Pm |
| Genentech USA, INC. | $18.11 | 2019 | |
| Seqirus USA INC | $15.36 | 2024 | Flucelvax |
| Novartis Pharmaceuticals Corporation | $12.22 | 2019 | |
| Neos Therapeutics, Lp | $12.19 | 2020 | |
| Mission Pharmacal Company | $12.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Payne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.